MoonLake Therapeutics, a clinical-stage biotechnology company, has a
market cap of approximately $32.84 million as of October 2023. The company's main drug candidate, Sonelokimab, is a novel nano-antibody targeting IL-17A and IL-17F, showing promising results in clinical trials for inflammatory diseases.
6
answers
CryptoPioneer
Mon Nov 04 2024
With such a high
market cap, MoonLake Immunotherapeutics is ranked as the 3626th most valuable company globally based on our data.
Federica
Mon Nov 04 2024
Its market capitalization highlights the strong financial standing and potential growth opportunities for the company.
CryptoLordGuard
Mon Nov 04 2024
MoonLake Immunotherapeutics boasts a
market cap of $2.96 billion USD as of October 2024.
CryptoLordess
Mon Nov 04 2024
MoonLake Immunotherapeutics continues to attract investors due to its promising immunotherapy treatments and research.
Silvia
Mon Nov 04 2024
BTCC, a top cryptocurrency exchange, offers a range of services that cater to the needs of digital asset traders.